FSA compares the Invesco Global Structured Equity Fund and the Morgan Stanley Global Opportunity Fund.
Category: Research
Can pharma and biotech ease pain in a financial crisis?
Ten years after the global financial crisis of 2008, FSA notes that pharmaceutical, healthcare and biotech stocks weathered that year better than other sectors.
Invesco Great Wall tops best China fund ideas
Morningstar’s semi-annual report on China’s best mutual fund ideas chose 16 onshore funds based on fund manager experience, consistency in investment process and performance in several market cycles.
Multi-asset: A question of balance
FSA takes a look at top-performing multi-asset funds to see how “balanced” they are. The results might surprise.
Robo-advisor performance May 2018
As markets continued their climb in May after a correction earlier this year, how did FSA’s hypothetical investments with the region’s three robo-advisors perform?
HEAD-TO-HEAD: Invesco vs Schroders
FSA compares the Invesco Euro Corporate Bond Fund with the Schroder ISF Euro Corporate Bond Fund.
Study: Asia’s HNWIs expect outsized SI returns
High net worth individuals in Asia put strong returns ahead of building a better world when it comes interest in sustainable investment (SI) products, according to a survey conducted by Standard Chartered.
HEAD-TO-HEAD: First State vs Value Partners
FSA compares the First State Asian Equity Plus Fund and the Value Partners High-Dividend Stocks Fund
What is lacking in Hong Kong’s ETF market?
Assets in Hong Kong’s ETF industry have grown threefold in the last 10 years, but the market remains small and lacks product diversification, according to Mohamed M’Rabti, Brussels-based head of ETFs at settlement firm Euroclear.
How HK’s tracker fund became more Chinese
The changing exposure of Hong Kong’s flagship equity ETF to Chinese large cap companies illustrates ever closer financial and economic ties between the territory and the mainland.
